Oxcarbazepine
Home / API - Commercial / Oxcarbazepine
CAS No.
28721-07-5
Therapeutic Category
- Anti-convulsant
Innovator Brand
TRILEPTAL / OXTELLAR
GMP
Available
DMF
Not Available
Filed
Under Filing
Sample
Available
Indication
Oxcarbazepine is indicated as monotherapy in the treatment of partial-onset seizures in patients 4 years of age and older, and as adjunctive therapy in the treatment of partial-onset seizures in patients 2 years of age and older.
Disclaimer: CTX Lifesciences respects patent laws and conventions of pharmaceuticals as applicable in different countries.
API/Substances covered by patent are not offered to the countries where the patent law is in force. However, the final responsibility lies with the customer.